Hepatic Fibrogenesis in Paediatric Cholestatic Liver Disease.

小儿胆汁淤积性肝病中的肝纤维发生。

基本信息

  • 批准号:
    nhmrc : 290220
  • 负责人:
  • 金额:
    $ 16.95万
  • 依托单位:
  • 依托单位国家:
    澳大利亚
  • 项目类别:
    NHMRC Project Grants
  • 财政年份:
    2004
  • 资助国家:
    澳大利亚
  • 起止时间:
    2004-01-01 至 2006-12-31
  • 项目状态:
    已结题

项目摘要

Liver disease in children causes a significant impact on lifespan and quality of life. The commonest causes of liver disease in children are cholestatic, or diseases related to obstruction of bile flow out of the liver. In ways we are only beginning to understand, obstruction of bile flow stimulates liver scar formation which, if untreated, leads to replacement of normal liver tissue and ultimately to failure of the liver. In infants, the most common and serious cholestatic liver disease is biliary atresia. It develops at, or shortly after birth with progressive destruction of the bile ducts, responsible for transporting bile out of the liver. Without early diagnosis and surgery these infants develop progressive liver scarring leading to liver failure and death or liver transplantation within 1-2 years. It is the commonest reason for liver transplantation in children (55-60%) in the Western world. Even with successful surgery, most, if not all patients will come to liver transplantation over the subsequent 25 years because of ongoing, but slower, scar formation. In older children, diseases like cystic fibrosis cause bile duct blockages leading to progressive liver scarring that is slower and unpredictable, contributing to ill health in up to 20% of patients and death from end stage liver disease or liver transplantation in 5%. Using liver tissue from children with these two disorders we have been able to identify the key cells that control the liver scar process, the Hepatic Stellate Cell. We now need to investigate the role of bile constituents on the scar-forming process in these two diseases. We will utilise a well characterised animal model to investigate the influence of bile constituents on cells isolated from this model and apply these findings back to patient samples to determine their role in paediatric cholestatic liver disease. This will help us to better understand the disease process and importantly, develop more effective and earlier treatment.
儿童肝脏疾病对寿命和生活质量造成重大影响。儿童肝病最常见的病因是胆汁淤积症,或与胆汁流出肝脏受阻有关的疾病。以我们刚刚开始了解的方式,胆汁流动阻塞会刺激肝瘢痕形成,如果不治疗,会导致正常肝组织的替代,最终导致肝脏衰竭。在婴儿中,最常见和严重的胆汁淤积性肝病是胆道闭锁。它在出生时或出生后不久随着负责将胆汁从肝脏输送出去的胆管的逐渐破坏而发展。如果没有早期诊断和手术,这些婴儿会在1-2年内出现进行性肝瘢痕形成,导致肝功能衰竭和死亡或肝移植。在西方世界,这是儿童肝移植最常见的原因(55-60%)。即使手术成功,大多数(如果不是全部)患者也会在接下来的25年里进行肝移植,因为疤痕的形成正在进行,但速度较慢。在年龄较大的儿童中,囊性纤维化等疾病会导致胆管阻塞,导致进展缓慢且不可预测的肝脏瘢痕形成,导致高达20%的患者健康状况不佳,5%的患者死于终末期肝病或肝移植。利用患有这两种疾病的儿童的肝脏组织,我们已经能够确定控制肝疤痕过程的关键细胞,肝星状细胞。我们现在需要研究胆汁成分在这两种疾病的疤痕形成过程中的作用。我们将利用一个特征良好的动物模型来研究胆汁成分对从该模型中分离的细胞的影响,并将这些发现应用到患者样本中,以确定它们在儿科胆汁淤积性肝病中的作用。这将帮助我们更好地了解疾病过程,更重要的是,开发更有效和更早的治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

A/Pr Peter Lewindon其他文献

A/Pr Peter Lewindon的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('A/Pr Peter Lewindon', 18)}}的其他基金

Role of Chemoattractants in Hepatic Stellate Cell Recruitment and Fibrogenesis in Paediatric Cholestatic Liver Disease.
化学引诱剂在小儿胆汁淤积性肝病肝星细胞募集和纤维形成中的作用。
  • 批准号:
    nhmrc : 496602
  • 财政年份:
    2008
  • 资助金额:
    $ 16.95万
  • 项目类别:
    NHMRC Project Grants
A trial of position control therapy for treatment of infantile gastro-oesophageal reflux
体位控制疗法治疗小儿胃食管反流的临床试验
  • 批准号:
    nhmrc : 508053
  • 财政年份:
    2008
  • 资助金额:
    $ 16.95万
  • 项目类别:
    NHMRC Project Grants

相似海外基金

Elucidating the Role and Regulation of Proteostasis in Hepatic Fibrogenesis
阐明蛋白质稳态在肝纤维形成中的作用和调节
  • 批准号:
    10718882
  • 财政年份:
    2023
  • 资助金额:
    $ 16.95万
  • 项目类别:
Dissecting the Acid Ceramidase Pathway in Hepatic Fibrogenesis
剖析肝纤维形成中的酸性神经酰胺酶途径
  • 批准号:
    10736680
  • 财政年份:
    2023
  • 资助金额:
    $ 16.95万
  • 项目类别:
Discovering Extracellular Modulators of Lung Fibrogenesis by Profiling Newly Synthesized Extracellular Matrix
通过分析新合成的细胞外基质发现肺纤维生成的细胞外调节剂
  • 批准号:
    10683787
  • 财政年份:
    2022
  • 资助金额:
    $ 16.95万
  • 项目类别:
Fibrogenesis Targeted Manganese Based MRI Contrast Agent
纤维发生靶向锰基 MRI 造影剂
  • 批准号:
    10726638
  • 财政年份:
    2022
  • 资助金额:
    $ 16.95万
  • 项目类别:
Ceramide, AMPK, and YAP/TAZ Signaling in Hepatic Fibrogenesis
肝纤维形成中的神经酰胺、AMPK 和 YAP/TAZ 信号转导
  • 批准号:
    10352024
  • 财政年份:
    2022
  • 资助金额:
    $ 16.95万
  • 项目类别:
Fibrogenesis Targeted Manganese Based MRI Contrast Agent
纤维发生靶向锰基 MRI 造影剂
  • 批准号:
    10547505
  • 财政年份:
    2022
  • 资助金额:
    $ 16.95万
  • 项目类别:
Ceramide, AMPK, and YAP/TAZ Signaling in Hepatic Fibrogenesis
肝纤维形成中的神经酰胺、AMPK 和 YAP/TAZ 信号转导
  • 批准号:
    10544748
  • 财政年份:
    2022
  • 资助金额:
    $ 16.95万
  • 项目类别:
HIV-induced monocyte and macrophage perturbations driving liver fibrogenesis
HIV诱导的单核细胞和巨噬细胞扰动驱动肝纤维化
  • 批准号:
    10647917
  • 财政年份:
    2022
  • 资助金额:
    $ 16.95万
  • 项目类别:
Immunomodulation of Galectin-3 to Prevent Radiation-Induced Myocardial Fibrogenesis
Galectin-3 的免疫调节预防辐射诱导的心肌纤维形成
  • 批准号:
    10353400
  • 财政年份:
    2021
  • 资助金额:
    $ 16.95万
  • 项目类别:
Immunomodulation of Galectin-3 to Prevent Radiation-Induced Myocardial Fibrogenesis
Galectin-3 的免疫调节预防辐射诱导的心肌纤维形成
  • 批准号:
    10570258
  • 财政年份:
    2021
  • 资助金额:
    $ 16.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了